Loading...
Docoh

ChemoCentryx (CCXI)

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Company profile

Ticker
CCXI
Exchange
CEO
Thomas Schall
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
ChemoCentryx Limited • ChemoCentryx Ireland Limited ...
IRS number
943254365

CCXI stock data

Calendar

8 Aug 22
2 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 45.48M 45.48M 45.48M 45.48M 45.48M 45.48M
Cash burn (monthly) (no burn) 2.73M 10.52M 10.97M 8.71M 4.46M
Cash used (since last report) n/a 8.49M 32.67M 34.05M 27.03M 13.84M
Cash remaining n/a 36.99M 12.81M 11.42M 18.45M 31.64M
Runway (months of cash) n/a 13.5 1.2 1.0 2.1 7.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Aug 22 Susan M Kanaya Common Stock Sell Dispose S No Yes 50.9495 19,898 1.01M 91,317
16 Aug 22 Susan M Kanaya Common Stock Option exercise Acquire M No No 10.86 19,898 216.09K 111,215
16 Aug 22 Susan M Kanaya Stock Option Common Stock Option exercise Dispose M No No 10.86 19,898 216.09K 35,102
4 Aug 22 Markus J. Cappel Common Stock Sell Dispose S No Yes 50.22 7,564 379.86K 87,658
4 Aug 22 Tyree James L Common Stock Sell Dispose S No Yes 50.22 10,000 502.2K 9,138
4 Aug 22 Susan M Kanaya Common Stock Sell Dispose S No Yes 50.1688 46,298 2.32M 91,317
4 Aug 22 Susan M Kanaya Common Stock Option exercise Acquire M No No 6.62 31,715 209.95K 137,615
4 Aug 22 Susan M Kanaya Common Stock Option exercise Acquire M No No 6.23 14,583 90.85K 105,900
4 Aug 22 Susan M Kanaya Stock Option Common Stock Option exercise Dispose M No No 6.62 31,715 209.95K 76,702
4 Aug 22 Susan M Kanaya Stock Option Common Stock Option exercise Dispose M No No 6.23 14,583 90.85K 30,209
97.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 185 178 +3.9%
Opened positions 39 21 +85.7%
Closed positions 32 38 -15.8%
Increased positions 72 69 +4.3%
Reduced positions 51 63 -19.0%
13F shares Current Prev Q Change
Total value 1.81B 1.63B +10.9%
Total shares 69.43M 66.53M +4.4%
Total puts 292.6K 1M -70.8%
Total calls 1.13M 1.33M -14.9%
Total put/call ratio 0.3 0.8 -65.7%
Largest owners Shares Value Change
FMR 10.68M $264.62M +0.5%
Biotechnology Value Fund L P 6.69M $72.96M 0.0%
Vanguard 5.81M $143.88M +13.4%
Vifor 5.19M $186.99M 0.0%
BLK Blackrock 4.64M $114.92M +8.0%
STT State Street 4.05M $100.26M +11.1%
Pictet Asset Management 2.37M $58.79M +28.9%
Wasatch Advisors 2.1M $52.11M +95.5%
Baker Bros. Advisors 1.79M $44.42M +95.5%
IVZ Invesco 1.72M $42.65M +6.8%
Largest transactions Shares Bought/sold Change
Hood River Capital Management 1.34M +1.34M NEW
Perceptive Advisors 441.68K -1.21M -73.3%
Avidity Partners Management 0 -1.18M EXIT
Ra Capital Management 0 -1.16M EXIT
Wasatch Advisors 2.1M +1.03M +95.5%
Millennium Management 370.69K -930.26K -71.5%
Baker Bros. Advisors 1.79M +875.8K +95.5%
Two Sigma Investments 11.5K -770.49K -98.5%
Vanguard 5.81M +686.91K +13.4%
Logos Global Management 600K +600K NEW

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: altered, Amgen, billion, Canada, chain, conflict, economy, enterprise, geopolitical, grow, inflation, Kingdom, Merger, outlook, staffing, stockholder
Removed: anticipation, attention, broad, lawsuit, section, volatility, volume